DNA medicines

Mechanism

Related News

Class Action Lawsuits Filed Against Atara Biotherapeutics and Inovio Pharmaceuticals

Apr 02, 2026

Class action lawsuits allege securities violations by Atara Biotherapeutics and Inovio Pharmaceuticals related to FDA submissions. Atara faces claims over manufacturing issues with its tabelecleucel BLA, while Inovio is accused of misleading statements about INO-3107 regulatory timelines and manufacturing deficiencies.

Inovio Stock Remains High-Risk Biotech Play Amid Clinical and Funding Uncertainty

Mar 01, 2026

Inovio Pharmaceuticals trades as a speculative micro-cap biotech on NASDAQ, with DNA medicine candidates in oncology and infectious disease facing binary clinical risks and ongoing capital needs.

Inovio Faces Securities Class Action Over INO-3107 BLA Delays and FDA Review Status

Feb 13, 2026

Multiple law firms have filed securities class actions against Inovio Pharmaceuticals after the FDA accepted its INO-3107 BLA for standard rather than accelerated review, following earlier manufacturing delays with the CELLECTRA device.